On May 7, 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) announced financial results for the second quarter of fiscal year 2026 that ended March 31, 2026 and provided a business update. The launch of REDEMPLO (plozasiran) continues to show strength with total prescriptions to date since launch over 400, which includes >40% growth over just the past four weeks. The company also secured positive regulatory action in four additional regions. Important clinical readouts in the second half of 2026 include SHASTA-3, SHASTA-4, and MUIR-3 in 3Q26 ARO-DIMER-PA in 3Q26 ARO-MAPT in late 3Q26 or early 4Q26 and ARO-INHBE and ARO-ALK7 in 2H26. On the business development front, Arrowhead recently signed a worldwide license agreement with Madrigal Pharmaceuticals for ARO-PNPLA3 that included a $25 million upfront payment from Madrigal with the potential for $975 million in development, regulatory, and sales milestones.
